From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.
At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a number of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.
Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.
BTIG analyst Marie Thibault came away from the conference with optimism around the diabetes space.
“While overall attendance at the ADA meeting felt low compared to pre-COVID and other medical meetings we’ve gone to this year, analyst and investor attendance seemed particularly high to us,” Thibault wrote in a report. “It is clear diabetes tech remains a high priority for the medtech investment community, in part because of the numerous catalysts and rapidly shifting market dynamics. We remain bullish on the space and expect sales growth rates to keep outpacing most of MedTech.”
Here is a breakdown of some of the biggest stories to come from the ADA 2023 Scientific Sessions:
